We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
GSK plc | NYSE:GSK | NYSE | Depository Receipt |
Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.23 | 0.53% | 43.58 | 43.68 | 43.27 | 43.58 | 4,048,068 | 01:00:00 |
By Denise Roland
GlaxoSmithKline PLC said net income ballooned in the first quarter of the year thanks to strong sales growth of the company's newer drugs, a boost from a weak pound, and a favorable year-earlier comparison.
The U.K. drug maker said net profit nearly quadrupled to 1.05 billion pounds in the first three months of the year, compared with GBP282 million a year ago, when earnings were hurt by a GBP489 million charge related to the re-evaluation of various joint ventures.
Adjusted operating profit, a measure that strips out one-time items, rose 30% to GBP1.98 billion, while revenue climbed 19% to GBP7.38 billion.
Glaxo, which reports in sterling but makes most of its revenue in other currencies, is benefiting from the weakness of the pound, which has fallen some 15% against the U.S. dollar and 10% against the euro since the U.K. voted to leave the European Union on June 23 last year.
Stripping out the currency effect, adjusted operating profit rose 9% and revenue climbed 5%.
Write to Denise Roland at Denise.Roland@wsj.com
(END) Dow Jones Newswires
April 26, 2017 07:59 ET (11:59 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions